Study #2015-0148
Phase II Trial Of Isatuximab With or Without Lenalidomide In Patients With High Risk Smoldering Multiple Myeloma
MD Anderson Study Status
Not Accepting
Treatment Agent
Isatuximab
Description
This is a multi-center, open label, phase II study designed to evaluate the efficacy of isatuximab with or without lenalidomide when given to patients with high risk smoldering multiple myeloma.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Smoldering Plasma Cell Myeloma
Study phase:
Phase II
Physician name:
Sheeba Thomas
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.